SEC Form 3 · accession 0001615774-18-001671
Boston Therapeutics, Inc. · BTHE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Loraine Upham
Officer — Chief Operating Officer
Period of report
Feb 12, 2018
Accepted (ET)
Mar 7, 2018 · 6:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001473579
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value per share | holding | — | — | — | 777,429 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $0.06 | holding | — | — | — | Feb 12, 2019 | — | Common Stock, $0.0001 par value per share | 1,333,333 | — | D |
| Stock OptionsF1 | $0.10 | holding | — | — | — | — | — | Common Stock, $0.0001 par value per share | 1,333,333 | — | D |
| Stock OptionsF1 | $0.20 | holding | — | — | — | — | — | Common Stock, $0.0001 par value per share | 1,333,333 | — | D |
Explanation of responses
- F1Ms. Upham received a stock option to purchase 4,000,000 shares of common stock under the Company's Amended and Restated 2011 Stock Incentive Plan, vesting over three (3) years, one third on the first anniversary of the option grant date and the balance in equal quarterly installments. The exercise price of the initial tranche of options (1,333,334 shares) shall be $0.06 per share, the second tranche (1,333,333 shares) shall be $0.10 per share and the final tranche (1,333,333 shares) shall be $0.20 per share. The term of the options is five years.